Výsledky vyhledávání - "Eva, Kohegyi"

Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Autor: Lenard A, Adler, Julie, Adams, Jessica, Madera-McDonough, Eva, Kohegyi, Mary, Hobart, Denise, Chang, Mark, Angelicola, Robert, McQuade, Michael, Liebowitz

Publikováno v: Journal of Clinical Psychopharmacology. 42:429-439

Centanafadine is an inhibitor of norepinephrine, dopamine, and serotonin reuptake transporters under investigation for the treatment of attention-deficit/hyperactivity disorder (ADHD).Two phase 3 randomized, double-blind, placebo-controlled, parallel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a536bae836029022f18b069243588f20
https://doi.org/10.1097/jcp.0000000000001575

Zobrazit plný text záznamu

Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies

Autor: Eva Kohegyi, Timothy E. Wilens, Anthony McKinney, Timothy Wigal, Mary Hobart, Sharon B. Wigal, Jessica J Madera, Ross A. Baker

Publikováno v: Neuropsychiatric Disease and Treatment. 16:1411-1426

Purpose Two phase 2 studies evaluated the efficacy and tolerability of centanafadine sustained-release (SR) for adults with attention-deficit/hyperactivity disorder (ADHD). Patients and Methods In a phase 2a, flexible-dose, single-blind study, 41 mal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::64bee169e4f041abd49d6867323a1c78
https://doi.org/10.2147/ndt.s242084

Zobrazit plný text záznamu

Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials

Autor: Robert D. McQuade, Jeffrey L. Cummings, Mary Slomkowski, Didier Meulien, George T. Grossberg, Victor Mergel, Mary Hobart, Eva Kohegyi, Ross A. Baker, Mette Krog Josiassen

Publikováno v: The American Journal of Geriatric Psychiatry. 28:383-400

Objective To assess the efficacy, safety, and tolerability of brexpiprazole in patients with agitation in Alzheimer's dementia (AAD). Design Two 12-week, randomized, double-blind, placebo-controlled, parallel-arm studies (NCT01862640; NCT01922258). S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5a5a25a79650d61110ec2084cb52e31
https://doi.org/10.1016/j.jagp.2019.09.009

Zobrazit plný text záznamu

Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and Adolescents

Autor: Margaretta Nyilas, Robert D. McQuade, Joan Zhao, Floyd R. Sallee, Alet van Beek, Kevin Cox, Eva Kohegyi, Roger Kurlan, Raymond Sanchez, William H. Carson

Publikováno v: Journal of Child and Adolescent Psychopharmacology

Objectives: Aripiprazole modulates dopaminergic and serotonergic pathways that may play a role in the pathogenesis of Tourette's disorder (TD). This trial evaluated the efficacy and safety of oral aripiprazole in the suppression of tics in children a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::239f180f033fcf49337bd01dcb2e10c0
http://europepmc.org/articles/PMC5689110

Zobrazit plný text záznamu

Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study

Autor: Robert D. McQuade, William H. Carson, Phyllis M. Salzman, Eva Kohegyi, Margaretta Nyilas, Christoph U. Correll, Raymond Sanchez, Ross A. Baker, Cathy Zhao

Publikováno v: Journal of the American Academy of Child and Adolescent Psychiatry. 56(9)

Objective To evaluate the efficacy, safety, and tolerability of aripiprazole, a dopamine D 2 receptor partial agonist, as maintenance treatment in adolescent outpatients with schizophrenia. Method This was a multicenter, double-blind, placebo-control

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e6707e6a42057f3127729a6645a201c
https://pubmed.ncbi.nlm.nih.gov/28838583

Zobrazit plný text záznamu

T45. THE NEW YORK ASSESSMENT OF ADVERSE COGNITIVE EFFECTS OF NEUROPSYCHIATRIC TREATMENT (NY-AACENT): INITIAL VALIDATION FINDINGS

Autor: Gianna Capodilupo, Eva Kohegyi, Kazunori Tatsumi, Christoph U. Correll, Daniel Antonius, Cong Liu, Mark Opler, Ross A. Baker, Enrique Gaspar

Publikováno v: Schizophrenia Bulletin. 45:S221-S221

BACKGROUND: Adverse cognitive side effects of medications impact the functioning of patients with schizophrenia. There is a lack of scales that focus on drug-induced effects on cognition, particularly in adolescents with schizophrenia. The New York A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad9918fdc5048f80f61597d6159560aa
https://doi.org/10.1093/schbul/sbz019.325

Zobrazit plný text záznamu

Current Trends in the Development of New Antidepressants

Autor: Susanna Fürst, Pal Pacher, Valéria Kecskeméti, Eva Kohegyi

Publikováno v: Current Medicinal Chemistry. 8:89-100

Early antidepressant medications e.g. tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) are effective because they enhance either noradrenergic or serotonergic mechanisms, or both. Unfortunately, these compounds block choliner

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::756438efc576c7f3d7b681846ffd45fa
https://doi.org/10.2174/0929867013373796

Zobrazit plný text záznamu

Effects of Elevated Serum Prolactin on Bone Mineral Density and Bone Metabolism in Female Patients With Schizophrenia: A Prospective Study

Autor: Eva Kohegyi, Richard C. Josiassen, Wynn Wynn Paing, Joanne Kaminski, George Abraham, Ashok Joseph

Publikováno v: American Journal of Psychiatry. 160:1618-1620

Objective: This study was designed to prospectively examine differential effects of sustained “high” and “low” serum prolactin levels on bone mineral density and peripheral markers of bone metabolism. Method: A dual-energy X-ray absorptiomete

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17e62ee963605f17bf1c1b6d0f43b3a4
https://doi.org/10.1176/appi.ajp.160.9.1618

Zobrazit plný text záznamu

Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial

Autor: Wynn Wynn Paing, Ashok Joseph, Richard C. Josiassen, Mahmood Dadvand, Sudhir Stokes, Rita A. Shaughnessy, Eva Kohegyi

Publikováno v: The American journal of psychiatry. 162(1)

Objective: The authors evaluated the efficacy and safety of augmenting clozapine with risperidone in patients with treatment-resistant schizophrenia. Method: In a randomized, double-blind, placebo-controlled 12-week trial, 40 patients unresponsive or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad65433fd31b8fd7752acd40e28e9ea6
https://pubmed.ncbi.nlm.nih.gov/15625211

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání